Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 5
2010 3
2011 3
2012 4
2013 3
2014 5
2015 2
2016 1
2017 1
2018 1
2019 1
2020 4
2021 6
2022 4
2023 2
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes A, Gale R, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Huntly B, Russell NH, Dillon R. Othman J, et al. Among authors: ommen hb. Blood. 2024 Aug 15;144(7):714-728. doi: 10.1182/blood.2024024310. Blood. 2024. PMID: 38691678
Treatment of the elderly patient with haematological cancer.
Andersen N, Al-Mashadi AL, Rotbain EHC, Kristensen IB, Lauritsen TB, Poulsen CB, Ommen HB, Andersen CBL, El-Galaly TC, Abildgaard N. Andersen N, et al. Among authors: ommen hb. Ugeskr Laeger. 2024 Jan 22;186(4):V08230538. doi: 10.61409/V08230538. Ugeskr Laeger. 2024. PMID: 38305321 Free article. Review. Danish.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Othman J, et al. Among authors: ommen hb. Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096. Blood. 2024. PMID: 38364112
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: ommen hb. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
Altered Fibrinolysis in Hematological Malignances.
Bønløkke ST, Ommen HB, Hvas AM. Bønløkke ST, et al. Among authors: ommen hb. Semin Thromb Hemost. 2021 Jul;47(5):569-580. doi: 10.1055/s-0041-1725099. Epub 2021 May 31. Semin Thromb Hemost. 2021. PMID: 34058766
45 results